Hematology 2020 ASH Education Program: 62nd ASH® Annual Meeting and Exposition

694 Pages·2020·18.4 MB·English

by  Adam Cuker, Mario Cazzola, Stella T. Chou, Ann LaCasce, David Garcia

Hematology 2020
AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
62nd ASH® Annual Meeting and Exposition
Editors
Adam Cuker, MD, MS
Executive Editor, Hematology 2020
Associate Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Mario Cazzola, MD
Deputy Editor, Hematology 2020
Research Group Leader on Myeloid Neoplasms
Fondazione IRCCS Policlinico San Matteo and University of Pavia
Pavia, Italy
Stella T. Chou, MD
Deputy Editor, Hematology 2020
Associate Professor of Pediatrics
The Children’s Hospital of Philadelphia
University of Pennsylvania
Philadelphia, PA
Ann LaCasce, MD, MSc
Deputy Editor, Hematology 2020
Associate Professor of Medicine
Dana-Farber Cancer Institute
Boston, MA
David Garcia, MD
Special Section Editor, Hematology 2020
Professor of Medicine
University of Washington
Seattle Cancer Care Alliance
Seattle, WA
AMERICAN SOCIETY OF HEMATOLOGY • WASHINGTON, DC
©2020bytheAmericanSocietyofHematology
ISSN1520-4391(print),1520-4383(online)
Hematology,theASHEducationProgram,ispublishedan- CommitteeonEducationalAffairs
nuallybytheAmericanSocietyofHematology(ASH)inone MarcJ.Kahn,MD,MBA(’21)(Chair)
volumeperyear.
AnjaliAdvani,MD(’22)
Allbusinesscorrespondenceandpurchaseandreprintre- JenniferR.Brown,MD,PhD(’21)
questsshouldbeaddressedtotheAmericanSocietyofHe-
EldadDann,MD(’21)
matology,2021LStreet,NW,Suite900,Washington,DC
JamesForan,MD(’22)
20036,USA;phone:[phone];fax:[phone];e-mail:
[email protected]. NobukoHijiya,MD(’24)
MargaretKasner,MD,MSc(’22)
Hematology,theASHEducationProgram,isavailableonthe
Internetathttps://ashpublications.org/hematology. KahPoh(Melissa)Loh,MBBChBAO(’23)
CaseyL.O’Connell,MD(’23)
©2020bytheAmericanSocietyofHematology.Allrights
HeatherA.O’Leary,PhD(’23)
reserved.CopyrightisnotclaimedinanyworksoftheUnited
StatesGovernment.Exceptasexpresslypermittedinthis MarthaP.Mims,MD,PhD(’23)
statement,nopartofthispublicationmaybeused(asherein Miguel-AngelPerales,MD(’20)
afterdefined)inanyformorbyanymeansnoworhereafter AdrianaSeber,MD,MS(’21)
known,electronicormechanical,withoutpermissioninwriting
AndrewD.Zelenetz,MD,PhD(’21)
fromthePublisher,theAmericanSocietyofHematology.For
purposesofthisnotice,theterm“use”includesbutisnot
ExOfficio
limitedtoreproduction,photocopying,storageinaretrieval
system,translation,andtransmittal.ThePublisherhereby StephanieJ.Lee,MD,MPH(President)
consentstotheuseofthispublicationoranyparthereofforany MartinS.Tallman,MD(President-Elect)
noncommercialeducationalpurposewithinthehealthfield
JaneN.Winter,MD(VicePresident)
suchasclassroominstructionandclinicalandresidencytraining.
Thispublicationoranypartthereofmaybeusedforeducational
Liaisons
purposesatconferences,continuingeducationcourses,and
othereducationalactivity,providednofeeorothercompen- JessicaK.Altman,MD(JuniorEditor,ASH-SAP7)
sationischarged,therefore.Allmaterialssousedmustac- ChristopherFlowers,MD,MS(Co-Chair,2020Education
knowledgethePublisher’scopyrightthereinas“©2020bythe Program)
AmericanSocietyofHematology.”WhenrequestingthePub- AaronGerds,MD(SeniorEditor,ASH-SAP8)
lisher’spermissiontousethispublicationoranypartthereof,
SiobanKeel,MD(Co-Chair,2020EducationProgram)
pleasecontacttheCopyrightClearanceCenterat222Rosewood
LauraDeCastro,MD,MSc(Liaison,CommitteeonPractice)
Drive,Danvers,MA01923,USA;phone:[phone];fax:
978-750-4470;ortheAmericanSocietyofHematologyPublica- AdamCuker,MD,MS(ExecutiveEditor,Hematology;Senior
tionsDepartmentat2021LStreet,NW,Suite900,Washington, Editor,ASH-SAP7)
DC20036,USA;phone:[phone];fax:[phone]. RobertA.Brodsky,MD(Secretary)
ArticleCitations Cover:Neutrophils.Source:AnimatedHealthcareLtd/Science
CitearticlesinthisvolumebylistingAuthor(s),Title,Hema- PhotoLibrary.
tologyAmSocHematologyEducProgram.2020;2020:be- Coverdesign:BrianCannon,AmericanSocietyofHematology
ginningpagenumber-endingpagenumber. Interiordesign:DebraNaylor,NaylorDesign
ThisactivityissupportedbyeducationalgrantsfromAstraZeneca
HematologyRightsandPermissions
Pharmaceuticals,IncyteCorporation,Amgen,BristolMyers
TorequestpermissiontoreprintorreuseHematologyarticles,
Squibb,NovartisPharmaceuticalsCorporation,andJazz
figures,ortables,pleasevisittheHematologypageatthe
Pharmaceuticals.
CopyrightClearanceCenter(https://www.copyright.com/
search!detail.action?item=123598168&
detailType=advancedDetail).
Thepublisherdisclaimsresponsibilityforopinionsexpressed
bytheauthors.
ii
Contents
x Editors’Message
xi Reviewers
xii ContinuingMedicalEducationInformation
Ham-Wasserman Lecture
1 TherapeuticdevelopmentandcurrentusesofBCL-2inhibition
ANDREWW.ROBERTS
AMap for theChangingLandscape ofCLL
10 ApproachesforrelapsedCLLafterchemotherapy-freefrontlineregimens
LINDSEYE.ROEKERANDANTHONYR.MATO
18 EVIDENCE-BASEDMINIREVIEW
Treatmentofrelapsedchroniclymphocyticleukemiaaftervenetoclax
MEGHANC.THOMPSONANDANTHONYR.MATO
24 Chemotherapy-freefrontlinetherapyforCLL:isitworthit?
JOANNAM.RHODESANDJACQUELINEC.BARRIENTOS
33 Standardtreatmentapproachesforrelapsed/refractorychroniclymphocyticleukemiaafter
frontlinechemoimmunotherapy
CAROLMORENO
Acute Myeloid Leukemia—SoManyTreatment Options;HowDoYouDecide?
41 Doespatientfitnessplayaroleindeterminingfirst-linetreatmentofacutemyeloidleukemia?
EVANC.CHENANDJACQUELINES.GARCIA
51 Howtoapproachshareddecisionmakingwhendeterminingconsolidation,maintenancetherapy,
andtransplantationinacutemyeloidleukemia
ALISONR.WALKER
57 Managementoftoxicitiesassociatedwithtargetedtherapiesforacutemyeloidleukemia:whento
pushthroughandwhentostop
EUNICES.WANGANDJEFFREYBARON
Advances intheLaboratory Assessment ofHemostatic andThromboticDisorders
67 “TEGtalk”:expandingclinicalrolesforthromboelastographyandrotationalthromboelastometry
RITASELBY
76 Improvinginterpretationofgenetictestingforhereditaryhemorrhagic,thrombotic,andplatelet
disorders
MICHELEP.LAMBERT
82 EVIDENCE-BASEDMINIREVIEW
Laboratorysurveillanceofimmune-mediatedthromboticthrombocytopenicpurpura
ANGLIANDJOHANNAA.KREMERHOVINGA
Contents | iii
Aggressive Lymphomas: What Novel Approaches AreReady for Prime Time?
85 Canweuseepigeneticstoprimechemoresistantlymphomas?
JENNIFERE.AMENGUAL
95 Harnessinglymphomaepigeneticstoimprovetherapies*
HAOPENGYANGANDMICHAELR.GREEN
101 Noveltargetsinaggressivelymphoma
KAMIMADDOCKS
Beyond theMarrow
107 Specialpre-andposttransplantconsiderationsininheritedbonemarrowfailureandhematopoietic
malignancypredispositionsyndromes
CARMEMBONFIM
115 Extrahematopoieticmanifestationsoftheshorttelomeresyndromes
KRISTENE.SCHRATZ
Caringfor Patients withAcute Leukemia inCommunityHospitals: Who, What,and WhentoRefer?
123 Optimizingmanagementofacuteleukemiaincommunitycentersandwhentorefer
ANANDP.JILLELLA,JORGEE.CORTES,ANDVAMSIK.KOTA
129 Practicepatternsandoutcomesforadultswithacutemyeloidleukemiareceivingcareincommunity
vsacademicsettings
ANNAB.HALPERNANDROLANDB.WALTER
135 Updatesininfectionriskandmanagementinacuteleukemia
C.LOGAN,D.KOURA,ANDR.TAPLITZ
Challenging Situationsfor Patients with Aggressive Lymphomas
140 ApproachestoaggressiveB-celllymphomasinlessfitpatients
NANCYL.BARTLETT
148 Strategiesforintroducingpalliativecareinthemanagementofrelapsedorrefractoryaggressive
lymphomas
OREOFEO.ODEJIDE
154 StrategiesforaggressiveT-celllymphoma:divideandconquer
LAURENC.PINTER-BROWN
Chronic Transfusion Support:Challenging Cases
160 Challengesinchronictransfusionforpatientswiththalassemia
ASHUTOSHLAL
167 Outpatienttransfusionsformyelodysplasticsyndromes
ERICAM.WOODANDZOEK.MCQUILTEN
175 Socialaspectsofchronictransfusions:addressingsocialdeterminantsofhealth,healthliteracy,and
qualityoflife
JENNIFERWEBB
Diagnostic andPrognostic ModelsinVTEManagement: Ready forPrime Time?
184 Canpregnancy-adaptedalgorithmsavoiddiagnosticimagingforpulmonaryembolism?
WEE-SHIANCHAN
190 WhenItreatapatientwithacutepulmonaryembolismathome
FREDERIKUSA.KLOKANDMENNOV.HUISMAN
195 EVIDENCE-BASEDMINIREVIEW
Advancedtherapiesandextracorporealmembraneoxygenationforthemanagementofhigh-risk
pulmonaryembolism
RADHIKAGANGARAJUANDFREDERIKUSA.KLOK
iv | Hematology2020 | ASHEducationProgram
201 Whichpatientsareathighriskofrecurrentvenousthromboembolism(deepveinthrombosisand
pulmonaryembolism)?
FIONNUALAN´IA´INLEANDBARRYKEVANE
Genetic Testingfor Heritable HematologicDisorders101
213 Informedconsentforgenetictestinginhematology
JONATHANM.MARRON
219 Identifyingpotentialgermlinevariantsfromsequencinghematopoieticmalignancies
IRAL.KRAFTANDLUCYA.GODLEY
Handling Challenging Questions intheManagement ofCML
228 First-generationvssecond-generationtyrosinekinaseinhibitors:whichisbestatdiagnosisofchronic
phasechronicmyeloidleukemia?
VIVIANG.OEHLER
237 HowtomanageCMLpatientswithcomorbidities
JORGECORTES
243 Handlingchallengingquestionsinthemanagementofchronicmyeloidleukemia:whenisitsafeto
stoptyrosinekinaseinhibitors?
DELPHINEREA
Immunotherapy inMultiple Myeloma
248 Sequencingmultiplemyelomatherapieswithandafterantibodytherapies
NIELSW.C.J.VANDEDONK
259 EVIDENCE-BASEDMINIREVIEW
ShouldallnewlydiagnosedMMpatientsreceiveCD38antibody–basedtreatment?
CHARLOTTEL.B.M.KORSTANDNIELSW.C.J.VANDEDONK
264 Bispecifics,trispecifics,andothernovelimmunetreatmentsinmyeloma
GUIDOLANCMAN,JOSHUARICHTER,ANDAJAICHARI
272 FutureofCARTcellsinmultiplemyeloma
KITSADAWUDHIKARN,SHAMMAILANKODY,ANDERICL.SMITH
ImprovingSymptomControl for Children withHematological Malignancies
280 Improvingsymptomcontrolandreducingtoxicitiesforpediatricpatientswithhematological
malignancies
LILLIANSUNG,TAMARAP.MILLER,ANDROBERTPHILLIPS
IndolentLymphomas: AnswerstoSmoldering Questions
287 HowdoIsequencetherapyforfollicularlymphoma?
GILLESSALLES
295 Howdowesequencetherapyformarginalzonelymphomas?
ALESSANDROBROCCOLIANDPIERLUIGIZINZANI
306 Transformedlymphoma:whatshouldIdonow?
SONALISMITH
Infection Risk,Immunization Recommendations, andAntimicrobial Prophylaxis
312 Rituximabandeculizumabwhentreatingnonmalignanthematologicdisorders:infectionrisk,
immunizationrecommendations,andantimicrobialprophylaxisneeds
ELISSAR.ENGELANDJOLANE.WALTER
Contents | v
319 Practicalapproachtomonitoringandpreventionofinfectiouscomplicationsassociatedwith
systemiccorticosteroids,antimetabolites,cyclosporine,andcyclophosphamideinnonmalignant
hematologicdiseases
LUISMALPICAANDSTEPHANMOLL
328 Preventinginfectionsinchildrenandadultswithasplenia
GRACEM.LEE
ManagingToxicities ofTargeted TherapiesinCLL
336 ManagingtoxicitiesofBrutontyrosinekinaseinhibitors
ANDREWLIPSKYANDNICOLELAMANNA
346 Managingtoxicitiesofphosphatidylinositol-3-kinase(PI3K)inhibitors
ASHLEYHANLONANDDANIELLEM.BRANDER
357 Preventingandmonitoringfortumorlysissyndromeandothertoxicitiesofvenetoclaxduring
treatmentofchroniclymphocyticleukemia
KIRSTENFISCHER,OTHMANAL-SAWAF,ANDMICHAELHALLEK
MonoclonalGammopathies ofDetermined Significance
363 ManagementofALamyloidosisin2020
GIOVANNIPALLADINI,PAOLOMILANI,ANDGIAMPAOLOMERLINI
372 ManagementofWaldenstro¨mmacroglobulinemiain2020
JORGEJ.CASTILLOANDSTEVENP.TREON
380 Monoclonalgammopathiesofclinicalsignificance
ANGELADISPENZIERI
MoreAnxiety-Provoking Hematology Consults
389 ApatientwithGaucherdiseaseandplasmacelldyscrasia:bidirectionalimpact
ARIZIMRAN,ROSARUCHLEMER,ANDSHOSHANAREVEL-VILK
395 Histiocyticdisorders:insightsintonovelbiologyandimplicationsfortherapyofLangerhanscell
histiocytosisandErdheim-Chesterdisease
KENNETHMCCLAIN
400 Updatesonthediagnosisandmanagementofthemostcommonhereditaryporphyrias:AIPandEPP
MICHAELLINENBERGERANDKLEBERY.FERTRIN
Myelodysplastic Syndromes: What WeHave andWhat We Want
411 Existingagents,novelagents,ortransplantationforhigh-riskMDS
BARTL.SCOTT
418 Patientstratificationinmyelodysplasticsyndromes:howapuzzlemaybecomeamap
ANNESOPHIEKUBASCHANDUWEPLATZBECKER
426 Therapyforlower-riskMDS
HETTYE.CARRAWAYANDCANERSAYGIN
Myeloproliferative Disorders: Too ManyCells,TooFew Therapies
434 AppliedgenomicsinMPNpresentation
ALISONR.MOLITERNOANDHANNAHKAIZER
440 GenomicsofMPNprogression
ANANDA.PATELANDOLATOYOSIODENIKE
vi | Hematology2020 | ASHEducationProgram
450 Genomicsofmyelodysplasticsyndrome/myeloproliferativeneoplasmoverlapsyndromes
MRINALM.PATNAIKANDTERRAL.LASHO
460 EVIDENCE-BASEDMINIREVIEW
Myelodysplasticsyndrome/myeloproliferativeneoplasmoverlapsyndromes:afocusedreview
MRINALM.PATNAIKANDTERRALASHO
OutofBalance: Anemias Due toDisordered IronHomeostasis
465 Inheritedmicrocyticanemias
MARIADOMENICACAPPELLINI,ROBERTARUSSO,IMMACOLATAANDOLFO,ANDACHILLEIOLASCON
471 Globallookatnutritionalandfunctionalirondeficiencyininfancy
MICHAELB.ZIMMERMANN
478 Diagnosisandmanagementofirondeficiencyinchronicinflammatoryconditions(CIC):istoolittle
ironmakingyourpatientsick?
KLEBERYOTSUMOTOFERTRIN
Pediatric Hematological Malignancies: CARsfor Kids
487 ChimericantigenreceptorTcellsformatureB-celllymphomaandBurkittlymphoma
EMILYM.HSIEHANDRAYNEH.ROUCE
494 CARTcellsforotherpediatricnon–B-cellhematologicmalignancies
ADAMJ.LAMBLEANDREBECCAGARDNER
501 CARTcellsvsallogeneicHSCTforpoor-riskALL
CAROLINEDIORIOANDSHANNONL.MAUDE
508 EVIDENCE-BASEDMINIREVIEW
WhatistheroleforHSCTorimmunotherapyinpediatrichypodiploidB-cellacutelymphoblastic
leukemia?
AIMEEC.TALLEURANDSHANNONL.MAUDE
Platelet Transfusions for Hematology/Oncology Patients
512 DoesABOandRhDmatchingmatterforplatelettransfusion?
NANCYM.DUNBAR
518 Howwelldoplateletspreventbleeding?
DARRELLJ.TRIULZI
523 EVIDENCE-BASEDMINIREVIEW
Theuseofpremedicationsforplatelettransfusionsinpediatricpatients
MEGHANMCCORMICKANDDARRELLTRIULZI
527 Platelettransfusionrefractoriness:HowdoIdiagnoseandmanage?
CLAUDIAS.COHN
Selected Hemostasisand Thrombosis Topics inWomen
533 Managementofheavymenstrualbleedingonanticoagulation
BETHANYSAMUELSONBANNOW
538 EVIDENCE-BASEDMINIREVIEW
Abnormaluterinebleedinginusersofrivaroxabanandapixaban
AMANDAE.JACOBSON-KELLYANDBETHANYT.SAMUELSONBANNOW
542 Preventionandtreatmentofpostpartumhemorrhage:focusonhematologicalaspectsof
management
CLAIREMCLINTOCK
Contents | vii
547 Womenandbleedingdisorders:diagnosticchallenges
PAULAD.JAMES
TheBrain andPain inSickleCell Disease
553 Neuropathicpaininsicklecelldisease:measurementandmanagement
ALEXANDERGLAROSANDAMANDAM.BRANDOW
562 Optimizingthemanagementofchronicpaininsicklecelldisease
IFEYINWAOSUNKWO,HAZELF.O’CONNOR,ANDELNASAAH
TheEmergingRole ofTargetedTherapies andCell Therapy inTransplant
570 Next-generationcelltherapies:theemergingroleofCAR-NKcells
RAFETBASAR,MAYDAHER,ANDKATAYOUNREZVANI
579 Practicalaspectsofbuildinganewimmunotherapyprogram:thefutureofcelltherapy
JESU´SG.BERDEJA
Understanding Howto ManipulatetheImmune Systemin Immunotherapyfor Lymphoma
585 Fundamentalsofimmunologyforunderstandingimmunotherapyforlymphoma
STEPHENM.ANSELL
590 Immunotherapywithcells*
ELISEA.CHONGANDDAVIDL.PORTER
598 Immunotherapywithdrugs
YUNCHOIANDCATHERINES.DIEFENBACH
Nonanticoagulant Interventions inVenous Thromboembolism
606 Roleofvenousstentingforvenousthromboembolism
KARENBREEN
612 Thrombolytictherapyinacutevenousthromboembolism
THITACHIASAKULANDKENNETHA.BAUER
619 Inferiorvenacavafilters:aframeworkforevidence-baseduse
AMARH.KELKARANDANITARAJASEKHAR
629 EVIDENCE-BASEDMINIREVIEW
Doprophylacticinferiorvenacavafiltersintraumapatientsreducetheriskofmortalityorpulmonary
embolism?
AMARH.KELKARANDANITARAJASEKHAR
What HematologistsNeed toKnowAbout Givingand StoppingAspirin
634 Doesaspirinpreventvenousthromboembolism?
ROBERTDIEPANDDAVIDGARCIA
642 Combiningantiplateletandanticoagulanttherapyincardiovasculardisease
GEOFFREYD.BARNES
Yinand YangofAutoimmunity andImmunodeficiencies inHematology
649 Allogeneichematopoieticstemcelltransplantationinadultswithprimaryimmunodeficiency
EMMAC.MORRIS
661 Howtoevaluateforimmunodeficiencyinpatientswithautoimmunecytopenias:laboratory
evaluationforthediagnosisofinbornerrorsofimmunityassociatedwithimmunedysregulation
ROSHINIS.ABRAHAM
673 Treatmentofimmune-mediatedcytopeniasinpatientswithprimaryimmunodeficienciesand
immuneregulatorydisorders(PIRDs)
MARKUSG.SEIDEL
viii | Hematology2020 | ASHEducationProgram
Erratum
680 SanzGF.InMDS,ishigherriskhigherreward?HematologyAmSocHematolEducProgram.2019;2019:
381-390.
*Articles NotEligible for Continuing MedicalEducation Credit
95 Harnessinglymphomaepigeneticstoimprovetherapies
HAOPENGYANGANDMICHAELR.GREEN
590 Immunotherapywithcells
ELISEA.CHONGANDDAVIDL.PORTER
Contents | ix